Oncology Inc For The Development Suppliers & Manufacturers

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...

Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...

Envair Technology, rooted in the containment industry and formed by merging the expertise of Envair and TCS, provides innovative clean air technologies. The company offers a comprehensive range of products, including rigid isolators, microbiological ...

ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...

Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...

Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...

medPhoton develops & manufactures robotic imaging solutions for image guided radiation therapy & navigated surgery. medPhoton, a Salzburg based company founded as spin-off from radART institute of Paracelsus Medical University and the University ...

CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and has recently committed to using its unique technology to develop a ...

Stelvio Oncology utilizes an image based method of epigenetic markers to develop predictive diagnostics and novel therapeutics for cancer. Stelvio Oncology is developing a personalized approach to glioblastoma treatment. Our team has core ...

T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...